DongKook Pharmaceutical Co., Ltd.

DongKook Pharmaceutical Co., Ltd. produces and sells pharmaceutical products in South Korea and internationally. The company offers non-prescription and prescription drugs, quasi drugs, medical devices, active pharmaceutical ingredients, cosmetics, and other products. Its pipeline includes DKF-MB601, used to treat Hepatitis B; DKF-MB501, to treat obesity; DKM-412 and DKM-420 to treat osteoarthritis; DKF-313, indicated for benign prostatic hyperplasia; DKF-447, to treat diabetes; DKB-123, used for wound healing, tissue repair; and DKM-428, used to protect skin. In addition, the company develops DKF-424, for the treatment of gastroesophageal reflux disease; DKF-427, used to treat antithrombotic; DKF-460, to treat Dyslipidemia; DKF-5122, for the treatment of Fungal Infection; DKF-MA201 and DKF-MB201, an acromegaly drugs; DKF-MB101, indicated for immunosuppression; and DKF-MA101 and DKF-MA102 to treat prostate cancer. The company was formerly known as UEC & Co., Ltd. and changed its name to DongKook Pharmaceutical Co., Ltd. in March 1982. DongKook Pharmaceutical Co., Ltd. was founded in 1968 and is headquartered in Seoul, South Korea.